Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 8, 2006

View Archived Issues

Drug bioavailability increased by tight junction modulator AT-1002 in preclinical studies

Enrollment begins in pivotal study of NOV-002 in advanced NSCLC

Watson completes acquisition of Andrx

Accentia set to open enrollment in phase III chronic sinusitis study of SinuNase

Antigen Express' synthetic avian influenza vaccine to begin clinical trials

Abbott to acquire Kos

Phase III trials of tramiprosate cleared to continue

Ziopharm acquires indibulin from Baxter

Survival data for Erbitux in metastatic colorectal cancer

Numax achieves primary endpoint in RSV study

CRx-102 demonstrates positive effect in rheumatoid arthritis

Bremelanotide effective in diabetic and nondiabetic erectile dysfunction patients

Positive interim survival results for picoplatin in SCLC

Celgosivir combination therapy shows benefit in chronic HCV nonresponders

Enrollment advances in phase III Riquent study

Long-term efficacy of entecavir in hepatitis B reported

Respiratory syncytial virus/parainfluenza virus type 3 vaccine safe in phase I study

Studies assess effects of PF-03491390 in hepatitis C, liver transplantation

Several new studies of rotigotine presented

Phase III results show improvements in COPD measures with arformoterol

Ambrisentan does not interact with warfarin or sildenafil

BLA filing for Thrombin

Voraxaze BLA withdrawn, with plans to resubmit

Duetact now available in U.S.

orBec filed in Europe for GI GVHD

Recent Dabur patent describes novel peptide-based therapeutic agents for alopecia

Recent patents describe new antidiabetic agents

Recent patents cover new therapeutic agents for cancer

Positive phase Ib results for AZD-6244 against solid tumors, phase II trials initiated

Preclinical data on liposomal irinotecan, IHL-305, versus irinotecan

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 7, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Bio Korea 2026: US policy risks shift to execution framework
BioWorld
Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...